Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mezagitamab - Takeda

Drug Profile

Mezagitamab - Takeda

Alternative Names: Anti-CD38 mAb; TAK-079

Latest Information Update: 08 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura; Multiple myeloma; Myasthenia gravis
  • Phase I Systemic lupus erythematosus
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 13 Apr 2021 Takeda anticipates the approval of mezagitamab for Idiopathic thrombocytopenic purpura and Myasthenia gravis in 2025/2026 (Takeda pipeline, April 2021)
  • 06 Dec 2020 Updated pharmacokinetics data from a phase I/II trial in Multiple myeloma presented at the 62nd American Society of Haematology Annual Meeting (ASH-2020)
  • 31 Aug 2020 Phase-II clinical trials in Idiopathic thrombocytopenic purpura in USA (SC) (NCT04278924)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top